RPG Life Sciences Limited - Asset Resilience Ratio
RPG Life Sciences Limited (RPGLIFE) has an Asset Resilience Ratio of 10.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check RPGLIFE capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2026)
This chart shows how RPG Life Sciences Limited's Asset Resilience Ratio has changed over time. See RPG Life Sciences Limited balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down RPG Life Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RPGLIFE company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs839.00 Million | 10.58% |
| Total Liquid Assets | Rs839.00 Million | 10.58% |
Asset Resilience Insights
- Moderate Liquidity: RPG Life Sciences Limited has 10.58% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
RPG Life Sciences Limited Industry Peers by Asset Resilience Ratio
Compare RPG Life Sciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for RPG Life Sciences Limited (2017–2026)
The table below shows the annual Asset Resilience Ratio data for RPG Life Sciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 10.58% | Rs839.00 Million ≈ $9.07 Million |
Rs7.93 Billion ≈ $85.78 Million |
-29.24pp |
| 2025-03-31 | 39.81% | Rs2.62 Billion ≈ $28.32 Million |
Rs6.58 Billion ≈ $71.14 Million |
+15.80pp |
| 2024-03-31 | 24.01% | Rs1.23 Billion ≈ $13.32 Million |
Rs5.13 Billion ≈ $55.46 Million |
-5.13pp |
| 2023-03-31 | 29.14% | Rs1.22 Billion ≈ $13.22 Million |
Rs4.19 Billion ≈ $45.35 Million |
+25.41pp |
| 2022-03-31 | 3.73% | Rs128.60 Million ≈ $1.39 Million |
Rs3.45 Billion ≈ $37.27 Million |
+3.23pp |
| 2021-03-31 | 0.50% | Rs15.30 Million ≈ $165.46K |
Rs3.03 Billion ≈ $32.81 Million |
+0.46pp |
| 2020-03-31 | 0.04% | Rs1.20 Million ≈ $12.98K |
Rs2.67 Billion ≈ $28.85 Million |
0.00pp |
| 2019-03-31 | 0.05% | Rs1.20 Million ≈ $12.98K |
Rs2.51 Billion ≈ $27.17 Million |
-0.24pp |
| 2018-03-31 | 0.28% | Rs8.30 Million ≈ $89.76K |
Rs2.91 Billion ≈ $31.50 Million |
+0.08pp |
| 2017-03-31 | 0.20% | Rs5.00 Million ≈ $54.07K |
Rs2.46 Billion ≈ $26.63 Million |
-- |
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. … Read more